Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
Caris Life Sciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Caris Life Sciences's total debt was $393.27M at Sep 30, 2026. For fiscal 2025 it was $378.99M, down 0.1% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $378.99M | -0.1% |
| FY2024 | Dec 31, 2024 | $379.53M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $393.27M | +4.5% |
| Q2 FY2026 | Jun 30, 2026 | $393.15M | +5.2% |
| Q1 FY2026 | Mar 31, 2026 | $381.58M | +0.5% |
| Q4 FY2025 | Dec 31, 2025 | $378.99M | – |
| Q3 FY2025 | Sep 30, 2025 | $376.46M | – |
| Q2 FY2025 | Jun 30, 2025 | $373.71M | – |
| Q4 FY2024 | Dec 31, 2024 | $379.53M | – |
See a number that looks wrong?